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CHARACTERIZING THE FUNCTIONAL PHENOTYPE OF INFILTRATING 
MACROPHAGES IN MENINGIOMAS 
ALLISON R. MCHENRY 
ABSTRACT 
 Meningiomas are the most common primary brain tumors, yet few successful 
non-invasive treatment options are available for patients. Immunotherapy has provided 
new insights into treatments for solid tumors. The immune infiltrate of meningiomas has 
been broadly characterized, showing a significant monocytic cell content, but little is 
known about the phenotype and function of these myeloid cells within the tumor 
environment. As circulating monocytes differentiate into macrophages with highly plastic 
character within tissue, it remains to be seen how the macrophages in meningiomas are 
influencing the tumor. As many studies have described the presence of monocytic 
subpopulations within other solid tumors, we hypothesize that meningiomas contain two 
populations of myeloid cells: a pro-inflammatory macrophage-like population, and an 
immunosuppressive myeloid-derived suppressor cell (MDSC)-like population. We 
collected fresh tumor samples and processed them into a single-cell suspension. The cells 
were then stained with fluorescently labeled surface marker antibodies commonly found 
on macrophages and MDSCs. We used flow cytometry to quantify the myeloid 
populations, sorted the populations with a FACSAria™, and analyzed their gene 
expression profiles with NanoString® and TaqMan®. Two distinct myeloid populations 
were found in all analyzed tumor samples, varying in macrophage-like to MDSC-like 
ratios from tumor to tumor. Gene expression analysis of these populations confirmed the 
	  	   vi	  
sorting strategy and provided new clues into the identity and function of the myeloid cell 
populations infiltrating meningiomas. NanoString®	  results	  confirmed	  a	  high	  HLA-­‐DR	  gene	  expression	  in	  the	  HLA-­‐DR+	  sorted	  populations.	  The	  tumor	  HLA-­‐DR+	  population	  was	  found	  to	  have	  higher	  gene	  expression	  relative	  to	  the	  HLA-­‐DR-­‐	  population	  for	  chemoattractants	  such	  as	  IL8,	  CCL3,	  and	  CCL4.	  Compared	  to	  a	  healthy	  blood	  monocyte	  control,	  tumor	  myeloid	  cells	  expressed	  higher	  levels	  of	  the	  genes	  C3AR1,	  ROCK2,	  IL10,	  NOS2,	  IL18,	  and	  CSF2.	  Finally,	  qPCR	  analysis	  and	  NanoString®	  results	  showed	  high	  expression	  of	  the	  gene	  IL6	  in	  the	  non-­‐immune	  cell	  tumor	  cells	  (CD45-­‐).	  The	  IL6	  cytokine	  has	  been	  shown	  to	  induce	  MDSCs.	  These findings may have 
significant implications in identifying new targets in immunotherapy to stop tumor 
growth and increase survival outcomes.  
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INTRODUCTION 
 
Meningiomas are the most common primary tumor of the brain. According to a 
recent review of reported tumors from 2006-2010 by the Central Brain Tumor Registry in 
the United States (CBTRUS), meningiomas make up approximately 35% of all tumors 
originating in the brain (Ostrom et al., 2013). These tumors arise from the meninges, the 
protective membranes surrounding the brain and spinal cord. More specifically, they are 
thought to derive from the meningothelial cells of the arachnoid membrane, the second of 
three membrane layers making up the meninges. While these neoplasms do not actually 
invade brain or spinal tissue, their presence disturbs the space in which they are located 
causing symptoms ranging in severity from unnoticeable to the development of focal 
neurologic deficits. Though the large majority of these tumors are classified as benign 
lesions, there is significant heterogeneity in reoccurrence rates, cellular morphology, 
aggressiveness, symptoms and survival outcomes associated with meningiomas. 
The location of the tumor is an essential factor in determining the prognosis of the 
disease. Most meningiomas are found in the supratentorial compartment along the dural 
venous sinuses in the cerebral convexivity, parasagittal, and sphenoid wing regions.  Less 
commonly, meningiomas may be found near the skull base including regions of the optic 
nerve sheath, cerebellopontine angle, and choroid plexus (Hallinan, Hegde, & Lim, 
2013). Though these represent a smaller fraction of meningiomas, their complex location 
makes surgical resection more difficult, placing greater limitations on a patient’s 
therapeutic options. Meningiomas are also the most common spinal cord tumor and, 
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among spinal cases, arise often in the intradural spinal cord and cauda equine (Saraf, 
McCarthy, & Villano, 2011).  
 
Meningioma Classification 
 As meningiomas are highly heterogeneous, a general classification based on 
histology and pathology of individual cases is useful. The World Health Organization 
(WHO) recognizes 15 subtypes of meningiomas based on histological features that fit 
into a grading system built on morphologic criteria shown to correlate with prognosis 
(Table 1) (Louis et al., 2007). Over 80% of meningiomas are classified as benign WHO 
grade I (Willis et al., 2005).  Though this grade is classically benign there exists a high 
degree of intraclass variability regarding histology and recurrence rates.  Histological 
subtypes classified as grade I include meningothelial, psammomatous, secretory, 
fibroblastic, angiomatous, lymphoplasmacyte-rich, transitional, microcystic, and 
metaplastic (Louis et al., 2007). Approximately 5-15% of meningiomas are classified as 
WHO grade II atypical tumors. These are typically meningiomas with high mitotic 
activity or greater cellularity. Recurrence rates are higher (30-40%) in atypical grade II 
meningiomas than grade I. Finally, the WHO classifies anaplastic meningiomas as grade 
III. These metastatic grade III tumors only account for 1-3% of cases and have higher 
incidences of local invasion and metastasis, with reappearance rates of 50-80% (Saraf et 
al., 2011).  
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Table 1. The World Health Organization’s (WHO) classification of meningiomas. 
Grades are described by their pathology, frequency and recurrence rates (Louis et al., 
2007).  
 
WHO Grade Frequency Pathology Recurrence rates 
Grade I 80%-90% Benign 7%- 20% 
Grade II 5%-15% Atypical 30%-40% 
Grade III 1%-3% Anaplastic/ 
malignant 
50%- 80% 
 
Risk Factors and Incidence Rates  
The risk factors associated with the development of meningiomas include 
modifiable and non-modifiable incidences. A major modifiable risk factor associated 
with the development of meningioma is exposure to ionizing radiation. This is strongly 
confirmed by the tinea capitis cohort, atomic bomb survivors, reports of patients exposed 
to dental radiographs and other patients exposed to radiotherapy for the treatment of other 
medially related illnesses. These meningiomas are also more likely to be atypical or 
malignant (Saraf et al., 2011). Non-modifiable risk factors associated with the 
development of meningiomas include increased age and the female gender.  The most 
recent CBTRUS publication reported an average annual age-adjusted incidence of 
meningiomas in the total population to be 7.41 per 100,000 people, with a 4.44 incidence 
rate in males and 9.97 incidence rate in females (Ostrom et al., 2013).  Additionally, 
researchers have investigated the role of endogenous and exogenous hormones as a 
possible risk factor of meningiomas in females, but the results have been inconclusive 
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(Hatch et al., 2005). Age remains one of the most prominent risk factors, as incident rates 
increase drastically after the age of 65 and the 10-year survival rate decreases 
significantly (Ostrom et al., 2013). 
Genetic and familial aspects are also likely to play a role in higher risk of 
meningioma development. Studies have shown a significant association between type 2 
neurofibromatosis (NF2) and incidence of meningioma. Chromosome 22q12 germ line 
mutations inherited in an autosomal manner are the most common genetic condition 
associated with meningioma presentation (Martuza & Eldridge, 1988).  Though the 
possibility of genetic associations has not yet been explored fully, a recent study found 
that, of the sampled tumors showing inactivation of NF2, there is a subset that also 
showed recurrent oncogenic mutations in the AKT1 and SMO genes (Brastianos et al., 
2013). And, previous studies looking at genetic associations with meningiomas compared 
single nucleotide polymorphisms (SNPs) in 12 candidate genes and found the SNPs in 
the Ki-RAS and ERCC2 genes were associated with a higher risk for developing 
meningiomas (Sadetzki et al., 2005).  
 
Therapies and Treatment Options 
 The prognosis after being diagnosed with a meningioma varies greatly depending 
on the age of the patient, presenting symptoms, WHO grade of the tumor, and location of 
the tumor within the skull. A physician will often practice a wait-and-see approach if the 
patient is over the age of 65, especially if the tumor is asymptomatic and small. 
Meningiomas are slow growing and often go undiagnosed if asymptomatic, only to be 
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discovered post-mortem. Though most meningiomas are benign, their presence may lead 
to symptoms that vary depending on the location of the tumor. Symptoms may include 
headache, seizure, vision loss, facial numbness, weakness, loss of smell, or other focal 
neurological deficits (“Meningioma Symptoms & Diagnosis,” 2014). Surgical resection 
of a meningioma is the treatment option of choice for tumors located in operable regions 
(Norden, Drappatz, & Wen, 2009). Complete resection of a benign tumor is usually 
curative; however, grade II and III tumors have a high recurrence rate even with a total 
resection. Adjuvant therapies, such as radiation therapy (RT) and stereotactic 
radiosurgery (SRS), are recommended with higher-grade cases of meningiomas and for 
inoperable lesions (Norden et al., 2009). The use of SRS over RT may help reduce the 
amount of radiation damage to non-target tissues by converging several low dose beams 
of radiation on the tumor, multiplying the effect only at the target location (Dunn & 
Chiocca, 2013).  Advances in chemotherapeutics to treat meningiomas have been 
minimal, though some success was found using hydroxyurea (Norden et al., 2009). 
Immunotherapies are another avenue for drug development where we have yet to see 
significant breakthroughs.  
 
Immune Response to Tumors 
Little is known about the specific immune response to meningiomas, though an 
immune infiltrate in a range of human solid tumors has long been established. The 
presence of immune cells in tumors is indicative of the body’s attempt to eliminate 
aberrant cell growth. The controversial hypothesis arguing the existence of an 
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endogenous immune surveillance system against cancer, proposed by Burnet and 
Thomas, has been refined over the past few decades. The concept has evolved into a 
general understanding of the immune system’s response to cancer as it attempts to 
eliminate the tumor and mold the immunogenicity of tumor cells (Dunn, Bruce, Ikeda, 
Old, & Schreiber, 2002).  This response against neoplastic cells is known as 
immunoediting. Three phases of immunoediting have been proposed; including 
elimination, equilibrium, and escape (Dunn, Old, & Schreiber, 2004). In the elimination 
phase, cells of the innate immune system such as natural killer (NK) cells or 
macrophages survey the body and recognize and destroy neoplastic cells. They present 
tumor-antigens to naïve CD4 or CD8 T-cells and recruit an adaptive immune response to 
the tumor site for a stronger elimination response. If some of the tumor cells survive the 
elimination phase, the tumor may enter into the equilibrium phase where the lymphocytes 
prevent further tumor growth, but are not able to fully destroy the tumor cells. This phase 
is thought to last the longest, taking years before the tumor is diagnostically present 
(Dunn et al., 2004). Finally, genetic changes in the tumor cells and elements of the 
microenvironment are thought to provide resistance to immune destruction, and the tumor 
is able to proliferate and escape the immune system.  This relationship between tumors 
and the immune system is complex, but deciphering it is critical for the development of 
new therapeutics and biomarkers.  
Commonly, immune cells such as T and B lymphocytes, NK cells, macrophages, 
and dendritic cells infiltrate human solid tumors (Pagès et al., 2010). Though tissue 
inflammation is a natural mechanism for eliminating a pathogen or inciting event and 
	  7 
returning the tissue to homeostasis, inflammation in tumors has been linked to tumor 
survival and growth (Mantovani, Allavena, Sica, & Balkwill, 2008). In this case, the 
tumor environment subverts the adaptive immune responses against the tumor. Analysis 
of large groups of human tumors showed that the presence of memory T-cells with 
cytotoxic and Th1 profiles correlated with better survival outcomes (Pagès et al., 2010). 
Recently, the T cell and B cell immune infiltrate was characterized in meningiomas 
showing the presence of CD4 and CD8 effector T-cells and a subpopulation expressing a 
phenotype for exhaustion (Fang et al., 2013). The presence of these T cells is indicative 
of an inflammatory environment maintained by macrophages. Expansive cancer research 
has shown that macrophages, in fact, constitute a large part of tumor infiltrate (Long & 
Beatty, 2013). The phenotype of macrophages is highly pliable depending on the 
macrophages’ environment. Thus, it is no surprise that neoplastic cells are capable of 
creating a setting that polarizes macrophages to an anti-tumor or pro-tumor phenotype. 
Macrophages and monocytes are myeloid lineage cells originating in the bone 
marrow and commonly found in peripheral blood. Monocytes are precursors for 
macrophages, tissue residing phagocytic cells, and dendritic cells, the antigen-presenting 
messengers of the innate immune system. Monocytes extravasate from the systemic 
circulation into tissue, homed to the site by inflammatory signals. These cells respond to 
local cues and differentiate to specialize along different functional profiles that can be 
either pro-inflammatory or anti-inflammatory. Meningiomas have been shown to 
accumulate a significant monocytic infiltrate: two separate studies found some degree of 
monocytic infiltrate in all meningiomas (Morantz, Wood, Foster, Clark, & Gollahon, 
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1979; Sato, Kuratsu, Takeshima, Yoshimura, & Ushio, 1995, p. 2). Sato et al. reported a 
mean monocytic content of tumors to be 42% (ranging from 5% to 81%), while Morantz 
et al. reported a mean of 20% (ranging from 1% to 40%). Meningiomas have also been 
shown to express MCP-1, a chemoattractant for monocytes (Sato et al., 1995). Initial 
characterizations of the monocytic infiltrate have been done with immunohistochemistry 
that found that there are macrophage-like cells at the tumor/brain border in brain-invasive 
meningiomas, which correlates with a higher malignancy rate. But, tumors with an intact 
pial-glial basement membrane were associated with a diffuse monocytic infiltrate without 
clustering at the brain-tumor border, emphasizing heterogeneity of tumors and their 
immune infiltrate (Grund et al., 2009).  While immunohistochemistry is useful in 
identifying the presence of monocytic cells in tumors, the technique only looks at one 
stain leaving a void in the ability to distinguish any variations in the infiltrating myeloid 
cells. It needs to be determined whether the monocytic infiltrate is suppressing or 
enhancing the tumor growth. 
Myeloid-derived suppressor cells (MDSC) play an important role in regulating the 
immune response, specifically when the body is in a pathological state such as cancer. 
The origin of these cells is not fully understood but it is thought that they come from pro-
monocytes in the bone marrow and circulate in the peripheral blood and may also be 
induced by a tumor’s microenvironment (Figure 1) (Gabrilovich & Nagaraj, 2009). These 
cells have been found in most cancers examined, and correlate with more aggressive 
disease states (Youn & Gabrilovich, 2010). MDSCs are often found accumulated in and 
near tumors and lead to tumor immune tolerance. It is thought that tumors themselves 
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recruit, expand and activate MDSCs. In support of this, it was recently shown that 
monocytes from healthy individuals that were cultured with a number of diverse tumor 
cell lines converted to many MDSC-like phenotypes (Lechner et al., 2011; Rodrigues et 
al., 2010). Though it is not entirely clear how tumors are able to recruit and induce these 
cells, paradoxically it also appears that pro-inflammatory cytokines are able to induce 
them (Lechner, Liebertz, & Epstein, 2010).  
 
 
Figure 1. Proposed origin of myeloid-derived suppressor cells (MDSC). Myeloid cells 
originate in the bone marrow as pro-monocytes. They circulate in the peripheral blood as 
monocytes and differentiate into macrophages once at the target tissue. MDSC’s can be 
induced, depending on environmental cues, from the bone marrow or once inside the 
tumor.  
 
MDSCs are heterogeneous morphologically, phenotypically and functionally, 
making it difficult to define and identify these cells (Youn & Gabrilovich, 2010). Thus, 
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the best current way to define them is through their suppressive ability. MDSCs suppress 
both innate and adaptive immunity; they are potent suppressors of T cell responses such 
as proliferation and cytokine release. MDSCs may also induce regulatory T cells that 
further suppress T cell activation. Their suppression can be both antigen-dependent and 
independent. Immune suppression by MDSC will impede immunotherapies that require 
an active immune response and therefore they must be neutralized or removed for these 
therapies to be successful.   
Markers for Immune Cell Populations  	   Though the definitive characteristic of MDSCs is their ability to suppress T-cell 
proliferation, work has been done in defining common surface markers. The cluster of 
differentiation (CD) system is often used to identify surface receptors or ligands for the 
immunophenotyping of cells.  Some markers are found on all leukocytes and can be used 
to distinguish immune cells from the infiltrated tissue. Leukocyte Common Antigen 
(LCA) is commonly known as CD45 and, as its name suggests, is found on all immune 
cells as a protein-tyrosine phosphatase involved in activating and differentiating cells of 
the immune system. Lymphocytes are identified by other specialized surface markers. B-
cells express CD19, a protein that coordinates with B-cell antigen receptors. T-cells are 
commonly identified by the CD3 co-receptor, a component of the T-Cell Receptor 
complex required to activate T-cells. Myeloid cells contain many surface markers eligible 
for cell identification. CD33 is thought to be a good marker of myeloid lineage cells, and 
CD11b is another common myeloid marker (Freeman, Kelm, Barber, & Crocker, 1995). 
More differentiated myeloid subsets have more complex surface marker identification, 
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but many studies have added confidence to this identification, specifically macrophage 
and MDSC populations.  
 MDSCs in mice are defined as CD11b+, IL-4Ra+ and GR-1(low) with monocytic 
(CD14+) and granulocytic (CD16+) immunosuppressive subsets (Peranzoni et al., 2010). 
The MDSCs in humans are a heterogeneous population of immature myeloid (CD33+) 
cells, lacking markers of maturation (Lechner et al., 2011).  It has been established that 
tumor progression may be linked with gradual accumulation of immature myeloid cells in 
the blood and tumor site MDSC’s have been found to be significantly more prevalent in 
the peripheral blood of cancer patients (Diaz-Montero et al., 2009; Huang et al., 2013; 
Shen et al., 2013). Additionally, Almand et al. noted a substantially lower expression of 
MHC class II (HLA-DR) molecules on immature myeloid cells in cancer patients (2001). 
This lack of HLA-DR correlated with the suppression of a cytotoxic T cell response 
against cancer cells (Almand et al., 2001). Studies have shown a correlation between 
levels of MDSCs and the stage or severity of the cancer (Diaz-Montero et al., 2009). In 
these studies, MDSC’s from peripheral blood were identified as Lineage negative (Lin-), 
meaning the cells did not express cell surface markers of mature lymphoid or myeloid 
cells (CD3, CD19, CD57, CD14).  The population was thus defined as Lin-, HLA-DR-, 
CD33+, CD11b+ (Diaz-Montero et al., 2009). Additionally, an uneven balance between 
immature and mature myeloid cells is one of the trademarks of cancer and assists in 
tumor immune evasion and subsequent tumor progression (Kusmartsev & Gabrilovich, 
2002). 
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Table 2. Surface markers of immune cell populations. Previously established 
biomarkers of various immune cell subpopulations. All cell markers mentioned are found 
on the surface of the corresponding cells. 
 
Cell type Surface Marker 
All immune cells CD45+ 
B- cells CD19+ 
T- cells CD3+ 
Macrophage-like cells CD33+, CD14+, CD11b+, HLA-DR + 
MDSC-like cells CD33+ and/or CD11b+, HLA-DR- 
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SPECIFIC AIMS 
Though a robust immune infiltrate of monocytic cells has been described, the 
specific immune response to meningiomas remains to be elucidated (Morantz et al., 1979; 
Sato et al., 1995). Immune cells are highly plastic and, depending on their 
microenvironment and local stimuli, cells of the same lineage may become either pro-
inflammatory or immunosuppressive. We hypothesize that while the monocytic infiltrate 
of meningiomas is highly heterogeneous; a subset is composed of myeloid-derived 
suppressor cells (MDSC) with an immunosuppressive phenotype that potentially prevents 
the immune system from fighting off the tumor.  	   This study aims to identify the monocytic populations infiltrating meningiomas. 
We have perfected a method of processing fresh tumor tissue into a single-cell 
suspension for analysis. Based on previously published studies, we have utilized 
phenotypic markers of monocytic subpopulations to identify potentially pro-
inflammatory and immunosuppressive subsets. This will allow us to label the 
meningioma cell suspensions with accurate surface markers to detect different monocytic 
populations with flow cytometry. We leveraged the labeling information obtained to sort 
our monocytic subpopulations using fluorescence-activated cell sorting (FACS) on the 
BD FACSAria™ and subsequently analyzed the gene expression profile of the different 
populations with NanoString® and qPCR. The gene expression analysis allows for 
verification of cell purity and provides a more complete phenotypic profile of monocytic 
subpopulations, which we suspect will exhibit a pro-inflammatory macrophage-like 
profile and an immunosuppressive MDSC-like phenotype. 
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METHODS 
 
Meningioma Sample Processing 
Approximately 40 fresh meningioma tissue samples were obtained from Brigham 
and Women’s Hospital, Pathology Department and Yale University Medical School. 
Samples were received within 24 hours of surgical resection from the patient and 
processed into a single-cell suspension. In a sterile environment, the tumor samples were 
minced into small pieces (~1 mm^3) with a razor blade in a petri dish. Manual 
degradation of the tumor was supplemented with enzymatic digestion using a 1mg/mL 
solution of collagenase/dispase (C/D) (Sigma) and Phosphate Buffered Saline (PBS).  
The tissue slurry was placed on a shaker for one hour at 37 degrees Celsius to allow for 
complete collagenase digestion. The slurry was filtered through a 70 µm filter into a 50 
mL conical vial and washed with PBS three times. The cells were re-suspended in 1 mL 
of freezing media composed of 10% Dimethyl Sulfoxide (DMSO) and 90% Fetal Bovine 
Serum (FBS). The single-cell suspension was then quantified with a Nexcelom 
Bioscience Cellometer® cell counter using 20 µL Acridine Orange/Propidium Iodide 
(AO/PI) dual-fluorescence dye and 20 µL of cell. Additional milliliters of freezing media 
were added to dilute the cell suspension to approximately 1 x 10^6 cells/mL in 
accordance with the live cell count. The cell suspension was then aliquot into multiple 
cryo-vials of approximately 1 mL/vial and frozen at -80 degrees C (Figure 2).   
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Figure 2. Meningioma tissue processing protocol. Solid tumor samples were processed 
into a single-cell suspension using manual and enzymatic digestion techniques. The 
slurry was placed on a shaker for one hour then passed through a 70 µm filter into a 
conical tube. The cells were washed three times with PBS and re-suspended in 1 ml/ 1 x 
10^6 cells of freezing media (at 10% DMSO, 90% FBS). Samples were stored at -80° C 
until thawed for surface marker antibody staining. Stained cells were either (a) analyzed 
for surface markers or (b) sorted into subpopulations and analyzed for relative gene 
expression with FACSAria™.  
 
Cell Surface Staining for Flow Cytometry 
 One vial of processed cells from 25 meningiomas was selected for analysis. Each 
sample was thawed to room temperature. The single-cell suspension was then added to 10 
mL of PBS, inverted twice to disperse cells in buffer, and centrifuged at 1200 revolutions 
per minute (RPM) for 10 minutes. The supernatant was removed and the pellet re-
suspended. For every 1 x 10^7 cells, 40 µL of Anti-Biotin MicroBeads (Miltenyi) was 
added and incubated on ice for 15 minutes. The cells were then washed with 2 mL of 
Staining Buffer (SB) and centrifuged at 1200 RPM for 10 minutes. MACS® Miltenyi 
Biotec Cell Separation LS Columns were loaded onto a magnet and washed with 3 mL of 
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SB. The supernatant from the washed cells was removed and the pellet was re-suspended 
in 1 mL of SB and transferred to the columns. The columns were washed with 3 mL of 
SB three times. The cell solution that passed through the columns was then centrifuged at 
1200 RPM for 10 minutes, the supernatant removed, and the pellet re-suspended in 1 mL 
of SB. This procedure removed the majority of non-viable cells. The cells were counted 
and plated onto a 96-well round-bottom polypropylene plate and incubated with varying 
conditions of fluorescently labeled surface marker antibody on ice for 20 minutes. The 
staining conditions for each tumor sample included the following: (i) unstained (null), (ii) 
CD45- AF488 (BioLegend, clone HI30), CD33-PE (BD Biosciences), CD14-AF647 
(BioLegend, clone HCD14), and HLA-DR-PerCP (BD Biosciences), (iii) CD33-PE, 
CD11b-AF488, CD14-AF647, and HLA-DR-PerCP. The tumor samples were stained 
alongside a random healthy control blood sample. After incubation with the surface 
marker antibodies, 100 µL/well of SB was added and the plate was centrifuged at 2000 
RPM for 2 minutes. The supernatant was removed and the cells were washed with 200 
µL/well of SB and centrifuged at 2000 RPM for 2 minutes. After removing the 
supernatant, the cells were fixed with 150 µL/well of cold paraformaldehyde (PFA) at 
4% and incubated on ice for 20 minutes. The cells were then centrifuged again at 2000 
RPM for 2 minutes, supernatant removed, re-suspended in 200 µL/well of SB and 
transferred to FACS tubes. The cell populations were read on a BD FACSCalibur™ flow 
cytometer and analyzed using FlowJo software. 
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Cell Surface Staining for FACS Sorting 
 Using the same methods we used to stain samples for flow cytometric analysis, 
we processed 15 meningiomas to sort into subpopulation utilizing a fluorescence-
activated cell sorter (FACS). We stained the entire cell suspension from each tumor 
sample with surface antibodies CD33-PE, CD45-AF 488, and HLA-DR-PerCP.  Instead 
of transferring to FACS tubes, the stained cells were transferred to 15 mL tubes and 
diluted with 800 µL of SB. The cells were sorted using the FACSAria™ into the 
following populations: (i) CD45-, (ii) CD45+, CD33+, HLA-DR+, (iii) CD45+, CD33+, 
HLA-DR-. The number of events in each sorted cell population was recorded. The 
populations were sorted into cryo-vials of lysis buffer and frozen at -80 degrees C.  
 
RNA Isolation 
 The sorted populations of cells from the FACSAria™ analysis were thawed and 
RNA was extracted from the cell lysates using the Agilent Technologies® Absolute RNA 
Microprep Kit. Once extracted, a portion of the RNA was frozen at -80 degrees C and the 
remaining RNA was turned into cDNA.  
 
qPCR and TaqMan® 
 A portion of RNA from each sample was reverse-transcribed into cDNA by 
adding 20 µl of RNA and 30 µl of PCR solution into a 96-well Thermocycler plate. The 
PCR solution contained 5 µL RT Buffer (Applied Biosystems), 11 µL MgCl2 (Ambion), 
10 µL 2.5 mM dNTP Mix (Invitrogen, Life Technologies), 2.5 µL Random Hexamers 
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(Applied Biosystems), 1 µL RNase Inhibitor (Applied Biosystems), and 1.25 MuLV 
Reverse Transcriptase (Applied Biosystems) enzyme per well. The RNA and PCR 
solution was mixed well and put into the Thermocycler and run for 1 hour. The 
Thermocycler was set to run at 25 °C for 10 minutes, followed by 48 °C for 45 minutes, 
95.5 °C for 5 minutes and left at 4 °C until the plate was removed. The produced cDNA 
was stored in a -20 °C freezer until specific gene expression was analyzed with 
TaqMan® primers.  
TaqMan® gene expression analysis was performed on the cDNA from the 
meningioma sorted cell populations. A solution of 5 µL/ well of Taqman® Fast 
Advanced Master Mix, 0.5 µL/ well of housekeeping gene/endogenous control Beta-2-
Microglobulin, and 0.5 µL/ well of primer for the gene of interest, was made in a 
reservoir.  The solution was then added in the amount of 6 µL of solution per well to a 
384-well Thermo Scientific plate. The cDNA plate was thawed and 4 µL of cDNA per 
well was added to the 384-well plate with primer solution and mixed well. The samples 
were run on a ViiA™ Real-Time PCR System and data collected with ViiA™7 Software. 
 
Nanostring® Gene Expression Assay 
 To confirm the identity and further RNA profile of the FACSAria™ sorted tumor 
and immune sorted subpopulations, a gene expression analysis of the extracted RNA was 
performed using the NanoString Technology® nCounter GX Human Inflammation Kit.  
Results were analyzed using nCounter Software and GENE-E Software 
(http://www.broadinstitute.org/cancer/software/GENE-E/). 
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RESULTS 
 
 	   Approximately 40 meningioma tissue samples were received and processed into 
single-cell slurries. Samples obtained within 24 hours had good cell viability (50-80%). 
The few meningioma samples that did not arrive within 24 hours of surgical resection 
showed significant cell death and dismal cell counts. The extent of manual tissue 
digestion affected the cell count as well. A greater degree of physical tissue separation 
allowed the C/D to enzymatically digest the tissue more easily and freed more cells to 
pass through the 70 µL filter into the 50 mL collection tube. Cell count and viability at 
the conclusion of tumor processing varied highly by sample with a range of 1.0 x 10^4 to 
3.0 x 10^6 cells per sample and an average cell viability around 50%. We were able to 
collect and freeze between 1 to 3 vials of cell-slurry per tumor with approximately 1.0 x 
10^6 cells/vial. When samples were thawed and counted again before staining, the cell 
numbers were slightly decreased but the viability remained approximately the same. 
Artifacts due to multiple freeze-thaw cycles were prevented by removing samples from 
the -80 degree freezer only once, a few minutes before staining. Identical freezing media 
was used to store healthy patient peripheral blood mononuclear cells (PBMC).  
 
Flow Cytometry 
The FACSCalibur™ flow cytometric analysis provided a general picture of the 
immune cell populations in the tumors based on the fluorescent surface markers staining 
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the cells. Analyzing the tumor samples for immune cell subpopulations required 
experimentation with staining using a combination of fluorescently labeled surface 
marker antibodies. Based on the literature, we selected surface markers known to 
distinguish separate pro-inflammatory and immunosuppressive myeloid populations 
(Almand et al., 2001). The combination of CD33, CD11b, CD14, and HLA-DR markers 
was tested on tumor samples against PBMCs from a healthy blood sample control.  As 
CD33 and CD11b are both strongly expressed on myeloid cells, these cells were selected 
for first and, of that myeloid population, were analyzed for HLA-DR positive (pro-
inflammatory, macrophage-like) and HLA-DR negative (immunosuppressive, MDSC-
like) character. When selecting for the CD33 myeloid population first, a greater 
separation of HLA-DR+ and HLA-DR- subpopulations were apparent (Figure 3). We 
also initially looked at the expression of CD3 and CD19 in the tumor sample and blood 
control for T-cells and B-cells, respectively. A small population of CD3 T-cells and even 
smaller population of CD19 B-cells were present, consistent with previously reports in 
the literature (Domingues et al., 2012; Fang et al., 2013).  
Tumor cells are known to aberrantly express cell surface markers of other known 
cell populations, including immune cells. After an initial evaluation of myeloid cell 
populations in the tumors, we substituted the CD11b- AF488 stain for CD45-AF488 to 
help us more clearly distinguish between the immune cells and the tumor cells. The 
CD45 (or LCA) surface marker is commonly found on all immune cells. We found that 
staining the remaining samples with CD45, CD33, CD14, and HLA-DR provided the 
clearest picture of the distinct immune cell populations in our tumor samples (Figure 3).  
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Figure 3. Flow cytometric gating strategy used to identify the macrophage-like and 
MDSC-like subpopulations infiltrating meningiomas. Single-cell suspension tumor 
samples were stained with CD45-488, CD33-PE, CD14-APC, and HLA-DR-PerCP. The 
side scatter (SSC) versus forward scatter (FSC) plot was gated to eliminate the likely 
dead cells and debris. A second gate was placed on CD45+ population to separate the 
immune cells from the meningioma tumor cells. Of the CD45+ population, the CD33+ 
myeloid cells were selected for and compared against HLA-DR and CD14 markers. Two 
distinct populations emerged: a CD14+/HLA-DR+ subpopulation with the macrophage-
like phenotype and a CD14-/HLA-DR- subpopulation with the MDSC-like phenotype. 
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 The flow cytometry analysis of multiple meningioma samples showed high 
heterogeneity in the myeloid infiltrate from tumor to tumor. The ratio of HLA-DR- to 
HLA-DR+ myeloid cells varied by tumor sample. Subpopulations ranged from 9.39% to 
56.8% HLA-DR- and 43.2% to 90.6% HLA-DR+ (Figure 4). Compared to the blood 
monocyte control, the tumor HLA-DR+ subpopulations consistently had much higher 
expression of the HLA-DR molecule than the HLA-DR+ healthy blood monocytes 
(Figure 5).   
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Figure 4. Flow cytometric analysis shows the ratio of HLA-DR- to HLA-DR+ 
myeloid cells varies from tumor to tumor.  Single-cell suspension tumor samples were 
stained with CD45-488, CD33-PE, CD14-APC, and HLA-DR-PerCP. Three tumor 
samples are shown compared with one blood control. (A) FACS analysis was performed 
by gating live cells in FSC v SSC. (B) The CD45+ (immune cells) were selected. (C) Of 
the CD45+ cells, CD33+ cells were selected to isolate the myeloid cells. (D) Then, HLA-
DR was examined. Between tumor samples, the monocytic infiltrate was highly 
heterogeneous. The ratio of immunosuppressive MDSC-like (HLA-DR-) cells to pro-
inflammatory macrophage-like (HLA-DR+) varied between tumors.  
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Figure 5. The tumor myeloid cell HLA-DR+ subset is HLA-DR++. Flow cytometry 
revealed two populations of myeloid cells within the tumors: one population with high 
expression of the MHC class II molecule (HLA-DR+) and another lacking the surface 
marker (HLA-DR-). Compared with blood monocytes (red peak), the HLA-DR+ tumor 
myeloid cells (blue and orange peaks) have much higher expression of the HLA-DR 
molecule. (Left) The histogram shown compares HLA-DR expression of monocytes in 
blood sample A to tumor 1. (Right) Another histogram shows the HLA-DR expression of 
monocytes in blood sample B to tumors 2 & 3.  
 
 
FACSAria™ Sorting Strategy 
With the staining marker and population data from the flow cytometry 
experiments, we selected CD45, CD33, and HLA-DR markers as good indicators of the 
distinct myeloid populations. We selected seven meningiomas that originally had two to 
three vials of sample and whose immune infiltrate we had previously analyzed with flow 
cytometry. We stained a second vial of sample per tumor, alongside healthy blood 
controls, with the three-color stain above and used the FACSAria™ cell sorter to collect 
sorted populations including non-immune cell tumor cells (CD45-), pro-inflammatory 
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macrophage-like cells (CD45+, CD33+, HLA-DR+), and immunosuppressive MDSC-
like cells (CD45+, CD33+, HLA-DR-). First, gates for the CD45+ and CD45- 
populations were selected using approximately the top and bottom 40% of cells 
respectively. From the CD45+ gate, another gate on the CD33+ cell population was 
created and those cells were then gated for positive and negative HLA-DR populations 
(Figure 6). 
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Figure 6. Example of the sorting strategy used to sort tumor samples and blood 
controls into three populations with FACSAria™. The non-immune tumor cells 
(CD45-), macrophage-like (CD45+, CD33+, HLA-DR+) and MDSC-like (CD45+, 
CD33+, HLA-DR-) myeloid populations in meningiomas were collected and saved for 
gene expression analysis. The scatter gate was created to exclude debris and dead cells 
from the sort. A gate against the doublets ensured high purity of collected cells. The P2 
gate collected the CD45- non-immune tumor cells. The P1 gate selected the CD45+ 
immune cells. From P1, the P3 gate selected the CD33+ myeloid cells. From P3, the P4 
HLA-DR- MDSC-like cells and the P5 HLA-DR+ macrophage-like cells were collected. 
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NanoString® Assay 
After isolating the RNA from the sorted tumor sample subpopulations, the 
NanoString® assay was performed using the two myeloid cell subpopulations from seven 
meningiomas, four pairs of control blood myeloid subpopulations, and two CD45- 
meningioma cell populations. RNA was analyzed for the expression of 184 human genes 
associated with differential expression in inflammation. This gene sampling contained a 
wide range of inflammation-related pathways, including cytokines, interleukins, 
integrins, oxidative stress responses, and T-cell activation. The raw data provided a 
numerical score, which was converted to relative expression using the housekeeping 
genes (Cltc, Gapdh, Gusb, Hprt1, Pgk1, Tubb).  
The entire assay’s results were mapped in a linked heat map using the program 
GeneE (http://www.broadinstitute.org/cancer/software/GENE-E/). Similarly sorted 
samples from various tumors and blood controls were clustered together based on their 
relative gene expression (Figure 7). The nature of the NanoString® assay allows for very 
sensitive detection, even among small samples with low cell counts. This was an 
advantage due to the variability in the number of cells and viability after meningioma 
tissue processing. However, artifacts in relative expression are possible due to the 
comparison of low expression values always picked up by the detectors.  To help correct 
for this, the genes containing relative expression raw scores of 40 or less were eliminated 
from the analysis.  
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Figure 7. Linked heat map of NanoString® gene expression results. GENE-E 
software was used to visually analyze relative gene expression in the samples. Relative 
expression (R.E.) of each gene for a give sample is represented by a color gradient from 
low R.E. in blue to high R.E. in red. Samples are listed across the top of the heat map in 
columns and genes analyzed on the inflammation NanoString® panel labeled in rows on 
the right side of the map. EMB_0xx are tumor samples and IGTB xxx are the blood 
controls. Similar samples (e.g. CD45- cells) correctly clustered together showing similar 
gene expression by the same cell type from tumor to tumor.	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The gene expression of HLA-DRA and HLA-DRB1 showed high relative 
expression in the tumor HLA-DR+ and blood HLA-DR+ sorted populations. The MDSC-
like HLA-DR- sorted myeloid population, as well as the CD45- tumor cell population 
showed very low levels of HLA-DRA and B1 gene expression (Figure 8). These results 
confirmed our HLA-DR FACS sorting strategy.  
 
A   B  
 
 
Figure 8: Relative gene expression of HLA-DR subunits in tumor and healthy blood 
cell subpopulations. The (A) HLA-DRA and (B) HLA-DRB1 genes encode the MHC 
class II cell surface receptor. High expression of these genes was found in the tumor and 
blood HLA-DR+ sorted populations, confirming our sorting strategy. (R.E.= relative 
expression) 
 
Genes more highly expressed in tumor HLA-DR+ vs. HLA-DR- 
A few genes were selected to graph based on large differences in expression 
between the subpopulations of cells. To emphasize this difference, a fold-change analysis 
was done on those genes to measure how much the relative expression changes between 
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tumor HLA-DR+ cells and tumor HLA-DR- cells. Twenty-six of the genes showed 2-fold 
higher expression or greater in HLA-DR+ cells than HLA-DR- cells (Figure 9a). A 
number of the genes with the highest fold-changes encode for chemokines: IL-8, CCL3, 
CCL4 and CXCL1 (Figure 9b-e). The CCL3 and CCL4 genes encode the protein CCL3 
and CCL4 respectively. They are also known as members of the Macrophage 
Inflammatory Protein 1 (MIP-1) group, a cytokine involved in acute inflammatory states, 
produced by macrophages. IL8, the gene that encodes the cytokine IL-8, had the highest 
fold-change when comparing the HLA-DR+ and HLA-DR- tumor myeloid populations. 
IL-8 is commonly secreted by macrophages. It binds to its receptor CXCR1 or CXCR2 
and is known to induce chemotaxis of neutrophils and granulocytes to the target tissue 
and stimulate phagocytosis. The gene CXCL1 encodes for the cytokine CXCL1, 
chemokine ligand 1, and is expressed by macrophages giving them neutrophil 
chemoattractant activity.  However, IL-8 and CXCL1 are also involved in angiogenesis 
and CXCL1 has mitogenic properties.  
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Figure 9. Genes more highly expressed in tumor HLA-DR+ than HLA-DR-. (A) 
Fold-change analysis between tumor HLA-DR+ to HLA-DR- myeloid subpopulations.  
Genes included exhibit at least 2-fold higher relative expression of the gene in HLA-DR+ 
cells over HLA-DR- cells in the tumor samples. (B-E) Graphs representing genes with 
some of the highest fold changes in the fold-change analysis. Each graph shows the 
relative expression (R.E.) of the three sorted tumor cell populations and control blood 
myeloid subpopulations.  
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Genes more highly expressed in tumor HLA-DR- vs. HLA-DR+ 
 
 A negative fold-change analysis was done to measure the gene expression 
difference between the HLA-DR- to HLA-DR+ cells infiltrating the tumors (Figure 10a). 
Only two genes showed a -2 fold-change (less than 0.5 fold-change value).  The gene 
C4A encodes for the complement protein C4A, part of the complement system and innate 
immune defense against pathogens. The gene LTB encodes for lymphotoxin-beta, a type 
II membrane protein and induces inflammatory responses (Figure 10b-c).  
 
  A
fold-change negative
C4
A
LT
B
AT
F2
NF
AT
C3
PT
K2
MA
PK
AP
K5
PL
CB
1
C1
R
TG
FB
3
0.0
0.5
1.0
1.5
Genes
Fo
ld
-c
ha
ng
e
 
B C  
Figure 10. Genes more highly expressed in tumor HLA-DR- vs. HLA-DR+. (A) 
Negative fold-change analysis between tumor HLA-DR+ to HLA-DR- myeloid subsets.  
Only C4A and LTB show a -2-fold-change in relative expression (R.E.). (B-C) Graphs of 
C4A and LTB showing the R.E. of the three sorted tumor cell populations and control 
blood myeloid subsets. 
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Higher Gene Expression in Tumor Macrophages than Blood Monocytes 
There are a number of genes that are more highly expressed in both tumor 
infiltrating myeloid cell populations compared to the control blood monocytes (Figure 
11).  IL10 encodes for the anti-inflammatory cytokine interleukin-10 and is primarily 
expressed by monocytes upon PD-1 activation (Said et al., 2010). IL-10 has been 
implicated in the regulation of MDSCs. Sinha et al. proposed that MDSCs are in fact 
interacting with macrophages to increase the production of IL10 (Sinha, Clements, Bunt, 
Albelda, & Ostrand-Rosenberg, 2007). Higher gene expression in tumor macrophages is 
also seen for the C3AR1 gene, a complement receptor involved in the complement 
system.  
Relative expression of ROCK2 was higher in the tumor populations than in the 
blood controls. The tumor HLA-DR- subpopulation showed the highest expression of 
ROCK2. This gene encodes for a rho-associated protein kinase that acts on the 
cytoskeleton and regulates shape and movement of cells. High expression may correlate 
with the function of tumor infiltrating myeloid cells dispersion through the tumor mass.  
The gene NOS2 encodes the inducible enzyme nitric oxide synthase, a free radical that 
mediates several biological processes involving the clearance of pathogens. NOS2 is 
known to be produced by MDSCs (Figure 11) (Wesolowski, Markowitz, & Carson, 
2013).    
Compared to healthy blood monocytes, IL18 was expressed highly in the tumor 
myeloid infiltrate. The IL18 gene encodes for the IL-18 pro-inflammatory cytokine. 
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Myeloid cells are known to increase production of IL-18 in the presence of activated T 
cells (Figure 11) (Vankayalapati et al., 2001).  
A relatively high expression of CSF2 was found in the tumor myeloid cell 
populations compared with the monocytic blood populations. CSF2 encodes for 
granulocyte-macrophage colony stimulating factor (GM-CSF). Among the various 
pathways MDSC are induced, GM-CSF has been implicated in the production of MDSCs 
in both human and mice (Figure 11) (Dolcetti et al., 2010; Kohanbash et al., 2013; 
Lechner et al., 2010).   
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Figure 11. Genes more highly expressed in tumor infiltrating myeloid cells than 
blood monocytes. Graphs show the relative expression of genes C3AR1, ROCK2, IL10, 
NOS2, IL18, and CSF2 in tumor sample subpopulations and blood controls.	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Increased Cytokine Expression in CD45- Tumor Cells 
 The CFS1 gene expression analysis showed relatively higher levels of expression 
in the tumor samples than the blood controls (Figure 12a). The HLA-DR+ and HLA-DR- 
subpopulations of myeloid cells in the tumor had approximately the same level of CFS1 
expression. However, one sample of tumor CD45- cells had the highest relative 
expression of CSF1. CSF1 encodes the macrophage colony-stimulating factor (M-CSF) 
involved in the proliferation, differentiation and survival of myeloid-lineage cells.  
Similarly, the IL-6 gene expression analysis showed that the two myeloid subpopulations 
in the tumor expressed more IL-6 than the blood subpopulations (Figure 12b). The two 
tumor myeloid subpopulations also had a similar level of expression, and one sample of 
CD45- tumor cells showed the greatest average relative expression for IL6. Interleukin-6 
is encoded by the IL6 gene and is a cytokine with pro-inflammatory and anti-
inflammatory roles. It has also been implicated in the induction of MDSC (Lechner et al., 
2010). Finding it intriguing that the CD45- tumor cell population showed higher IL6 gene 
expression, we measured IL6 in an additional eight CD45- tumor cell samples. Results	  were	  consistent	  with	  the	  NanoString®	  analysis;	  IL6	  expression	  was	  highest	  in	  the	  CD45-­‐	  non-­‐immune	  tumor	  cell	  population (Figure 12c). 
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Figure	  12.	  NanoString®	  analyzed	  genes	  with	  high	  expression	  in	  CD45-­‐	  tumor	  
cells	  and	  IL6	  Taqman®	  confirmation.	  (A-­‐B)	  Graphs from the NanoString® assay 
show the relative expression of genes CSF1 and IL6 in tumor sample subpopulations and 
blood controls. One tumor sample had high relative expression of genes CSF1 and IL6. 
(C) Taqman® analysis of eight other tumor samples for the IL6 gene confirmed the 
tumor CD45- populations on average have a higher relative expression of IL6.   
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qPCR/TaqMan® Assay 
 One gene of interest not found on the NanoString® codeset was PDL-1. This gene 
is known to be expressed on MDSCs. Quantitative PCR was performed on four sorted 
tumors and two sorted blood controls to determine the relative gene expression of PDL-1. 
The gene PDL-1 encodes for the programmed cell death ligand 1, and normally binds to 
its receptor on T-cells (PD-1) to inhibit T-cell proliferation. The highest expression of 
PDL-1 was in the tumor HLA-DR- myeloid populations, but not in all tumors (Figure 
13). Only two out of the four tumor samples amplified to reach a relatively high 
expression level. Of the populations analyzed for PDL-1, the cell population with the 
most consistent expression was the CD45- population with three out of the four tumor 
samples amplifying, but expression was at much lower levels.  
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Figure 13. Relative expression of PDL-1 in tumor and blood cell subpopulations 
from the TaqMan® assay. Relative to the blood myeloid subpopulations and the 
meningioma CD45- cells, the tumor population of HLA-DR- myeloid cells was the only 
population to express the PDL-1 gene. 
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DISCUSSION 
 
The immune infiltrate of meningiomas is composed of a heterogeneous group of 
myeloid cells that to date have been poorly characterized. The plastic nature of 
macrophages, depending on cues from their environment, makes them prime targets for 
investigation in tumor immunobiology. In this study, we described the presence of two 
distinct populations of myeloid cells in meningiomas and examined their gene expression 
profiles to further characterize the two subpopulations. 
 MDSCs, with an immunosuppressive phenotype, have been described in patients 
with a variety of cancer types (Lechner et al., 2011; Mandruzzato et al., 2009). However, 
their existence and function remains to be reported in meningiomas. In our investigation, 
we examined the pro-inflammatory and immunosuppressive character of the two myeloid 
populations, confirming a macrophage-like and MDSC-like phenotypic cell profile 
respectively.  
Recent advancements in the understanding of tumor MDSCs has eluded their 
tumor-promoting role in other solid tumors and led to better surface markers to identify 
them (Youn & Gabrilovich, 2010). Our characterization of the two subsets was based on 
these surface markers. We defined the pro-inflammatory macrophage-like population as 
expressing CD45+, CD33+, CD14+, HLA-DR+. The immunosuppressive MDSC-like 
population was characterized as CD45+, CD33+ (or CD11b+), CD14+, HLA-DR-. Flow 
cytometric analysis of a sampling of meningiomas showed the existence of two myeloid 
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subpopulations in every tumor tested. The tumor infiltrating macrophage-like HLA-DR+ 
subset had higher expression of HLA-DR molecules than HLA-DR+ blood monocytes. 
Moreover, the ratio of MDSC-like cells to macrophage-like cells varied from tumor to 
tumor. This may correlate with the disease state of the patient, the recurrence rate of the 
tumor, and the effectiveness of the treatment, though more work must be done before 
such conclusions are made.   
 Differences in the gene expression of the different cell subpopulations support the 
conclusion that the HLA-DR sorted populations are different myeloid subsets. The 
sorting strategy, using the combination of surface markers that unveiled the two myeloid 
populations in flow cytometry, was confirmed by the high HLA-DR gene expression in 
the HLA-DR+ sorted populations relative to the HLA-DR- cells. This finding verifies our 
labeling and sorting techniques. This also strengthens the hypothesis that MDSC’s 
(commonly found to be HLA-DR- in other tumors) are present in meningiomas.   
The gene expression profiles of each subset provided insight into the true 
character of the myeloid infiltrate. Some genes were more highly expressed in the tumor 
HLA-DR+ cells. These genes, namely CCL3, CCL4, and IL-8, all encode chemokines 
that are associated with pro-inflammatory macrophages. CCL3 and CCL4 encode 
cytokines that act as chemoattractants for leukocytes, especially NK cells and monocytes. 
This supports the hypothesis that there are macrophage-like cells acting in an anti-tumor 
function to recruit immune cells to the tumor. However, IL8 and CXCL1 are involved in 
angiogenesis, a tumor promoting function that complicates the immune response to the 
	  42 
tumor. In addition, CXCL1 is thought to be mitogenic. Factors that promote mitosis and 
cell division are generally considered to favor the progression and growth of the tumor.  
Notable among the gene expression results, IL6 and CSF1 seem to have a 
relatively high level of expression in the CD45- tumor cells compared to the myeloid 
subpopulations. Many studies have reported that both of the cytokines encoded by these 
genes induce MDSCs (Dolcetti et al., 2010; Lechner et al., 2010; Marigo et al., 2010). 
CSF1 encodes for the cytokine M-CSF that is an important regulator of survival, 
proliferation, and differentiation in monocytes and macrophages. IL6 encodes for the pro-
inflammatory cytokine IL-6 secreted by T cells and macrophages. Tumor cells that 
secrete higher levels of IL-6 and M-CSF promote a tumor environment with accumulated 
MDSC, consistent with our findings describing MDSC-like cells in the meningioma 
samples we analyzed.  
There is still much work to be done in defining the effects of these myeloid 
populations on meningiomas. The most telling identifier of MDSCs is their ability to 
suppress proliferation of T-cells, preventing the immune system from mounting a proper 
response against the tumor. In the future, functional assays to test the proliferation of T-
cells should be conducted by isolating the myeloid subpopulations and co-culturing them 
with T-cells. Further insights into the immune response to meningiomas may lead to 
novel strategies to modulate the immune system to enhance its natural ability to manage 
tumor growth. These therapies will allow for better outcomes and survival rates for 
patients with higher-grade tumors, particularly when surgical resection is not possible.   
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